The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of liquid biopsy for identifying emerging mutations (mut) and novel treatment options in luminal metastatic breast cancer (LMBC).
 
Alberto Gonzalez-Medina
No Relationships to Disclose
 
Andri Papakonstantinou
No Relationships to Disclose
 
Judit Matito
No Relationships to Disclose
 
Fiorella Ruiz-Pace
No Relationships to Disclose
 
Meritxell Bellet
Consulting or Advisory Role - Lilly; Novartis; Pfizer
Speakers' Bureau - Lilly; Novartis; Pfizer
 
Anna Suñol
No Relationships to Disclose
 
Miriam Arumí
No Relationships to Disclose
 
Esther Zamora
Honoraria - Novartis; Roche
Travel, Accommodations, Expenses - Lilly; Lilly; Pfizer; Roche
 
Carolina Ortiz
No Relationships to Disclose
 
Lucia Sanz
No Relationships to Disclose
 
Patricia Gómez Pardo
No Relationships to Disclose
 
Marina Gómez-Rey
No Relationships to Disclose
 
Roberta Fasani
No Relationships to Disclose
 
Clara Morales
No Relationships to Disclose
 
Vicente Peg
Consulting or Advisory Role - AstraZeneca; Bayer; Exact Sciences; MSD; Sysmex
Travel, Accommodations, Expenses - Roche
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; Novartis
Consulting or Advisory Role - Bayer; MSD Oncology
Travel, Accommodations, Expenses - Novartis
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Consulting or Advisory Role - Boehringer Ingelheim; Roche
Speakers' Bureau - Amgen; Ipsen; Libbs; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Merck
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Ax's Consulting; Byondis; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; ISSECAM; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; Seagen; Zymeworks
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim España (Inst); Bristol-Myers Squibb (BMS) (Inst); Cytomx Therapeutics (Inst); Daiichi Sankyo (Inst); Genentech (Inst); German Breast Group (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); International Breast Cancer Study Group (Inst); Lilly (Inst); Macrogenics (Inst); MedSIR (Inst); Menarini (Inst); Merus (Inst); Millennium (Inst); Millennium (Inst); Novartis Farmacéutica (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Ana Vivancos
Stock and Other Ownership Interests - Reveal Genomics
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Incyte (Inst); Merck (Inst); Roche (Inst)
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst)
 
Mafalda Oliveira
Honoraria - Eisai Europe; Guardant Health; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Pierre Fabre; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pierre Fabre; Roche